Rhoen-Klinikum AG
Rhoen-Klinikum AG (RHK.DE) Stock Overview
Explore Rhoen-Klinikum AG’s financial performance, market position, analyst ratings, and future outlook.
RHK.DE Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Rhoen-Klinikum AG (RHK.DE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $15.25.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 19.45 and a market capitalization of 796.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, offers in-patient, semi-patient, and outpatient healthcare services in Germany. Its hospitals offer treatment services, including rehabilitation of cardiovascular patients, hand surgery, neurological, psychosomatic, addiction therapy facilities, ophthalmology, trauma surgery, dentistry, thoracic, pulmonary, vascular, tumors, neurological conditions, and treatment of spinal column, joints, and heart diseases. It operates eight hospitals and 5,420 beds/places at five medical sites. The company is based in Bad Neustadt an der Saale, Germany.
Stefan Stranz
18,819
Salzburger Leite 1, Bad Neustadt an der Saale
1998